Paul Kortan
Virginia Mason Medical Center
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Paul Kortan.
Gastrointestinal Endoscopy | 1996
Richard A. Kozarek; Shirley L. Raltz; William R. Brugge; Robert H. Schapiro; Irving Waxman; H. Worth Boyce; John Baillie; Stanley Branch; Paul Stevens; Charles Lightdale; Glen A. Lehman; Stanley Benjamin; David E Fleischer; Andrew M. Axelrad; Paul Kortan; Norman E. Marcon
BACKGROUNDnConventional esophageal prosthesis placement has been associated with a 6% to 8% perforation rate and numerous postplacement complications. Expandable esophageal stents have been developed to preclude the above but there are few studies that have prospectively defined clinical results and subsequent stent-related complications.nnnMETHODSnAll patients who underwent esophageal Z-stent placement at nine university or referral hospitals were prospectively assessed. Data collected included patient demographics, acute and subacute placement problems, the ability to occlude airway fistulas, prestent and poststent dysphagia scores, and patient survival.nnnRESULTSnFifty-four of 56 patients (96%) with refractory dysphagia or malignant esophagoairway fistulae had 73 Z-stents successfully inserted. Initial distal deployment occurred in 13% of the patients and an additional 17% required balloon dilation to achieve maximal diameter. Acute placement complications occurred in 11% of patients and included severe pain (3), bleeding from necrotic tumor (2), and hiatal hernia intussusception (1). No perforations occurred. Eight of 11 patients (73%) had complete tracheoesophageal fistula occlusion and mean dysphagia score (+/- SD) improved from 2.6 (0.7) to 1.1 (1.2) (p < 0.01). Fifteen stents (27%) had delayed migration at a mean of 1 month and 3 required surgery for retrieval. Three patients had ultimate stent erosion resulting in bleeding in 2 (exsanguination 1) or fistula (treated with a conventional stent).nnnCONCLUSIONSnThe authors conclude that esophageal Z-stents can be placed safely and successfully in the majority of patients. The tendency of distal deployment during placement and subsequent migration problems at a time distant from placement in a patient subset deserve attention and are currently being addressed.
Gastrointestinal Endoscopy | 1997
Richard A. Kozarek; Shirley L. Raltz; Norman E. Marcon; Paul Kortan; Gregory Haber; Charles Lightdale; Peter Stevens; Glen A. Lehman; Douglas Rex; Stanley Benjamin; David E Fleischer; Roshan Bashir; Steven Fry; Irving Waxman; Jay Benson; John Polio
BACKGROUNDnAn initial multicenter study using a 21 mm flanged esophageal Z stent demonstrated excellent palliation but an 11% immediate complication rate at placement and a 27% migration rate at 1 month. This North American multicenter trial prospectively studied a 25 mm flanged Z stent to define its palliative ability and whether the increased diameter affected placement or migration problems.nnnMETHODSnFifty patients who had esophageal Z stents at seven university or regional referral hospitals were prospectively studied. Indications for prosthesis placement, previous therapy, patient demographics, incidence of concomitant tracheoesophageal fistula, and degree of dysphagia were defined, as were procedural and subsequent stent-related problems, survival times, the ability to occlude a tracheoesophageal fistula, and subsequent degree of dysphagia.nnnRESULTSnTwenty-four patients had infiltrating malignancy (16 exophytic and 10 extrinsic), 9 of whom had concomitant tracheoesophageal fistulas. Ten patients (20%) had misplaced stents requiring retrieval and replacement, 12 patients (24%) had subsequent stent-related problems including exsanguination (2), aspiration (3), tumor overgrowth (3), and postplacement migration (4) (8%). There was statistically significant improvement in prestent versus poststent dysphagia and two thirds of patients had complete occlusion of their tracheoesophageal fistula.nnnCONCLUSIONSnRedesign of the esophageal Z stent has decreased the migration rate without increasing placement or subsequent erosion problems. Its efficacy appears comparable to the currently marketed Z stent for the palliation of malignant dysphagia and occlusion of tracheoesophageal fistula.
Gastrointestinal Endoscopy | 1996
Richard A. Kozarek; Shirley L. Raltz; Norman E. Marcon; Paul Kortan; Charles J. Lightdale; P. Stevens; Glen A. Lehman; Douglas Rex; Stanley Benjamin; David E Fleischer; Irving Waxman
/data/revues/00165107/v65i5/S0016510707013983/ | 2011
Sarah Cho; Maria Cirocco; Nancy Basset; Paul Kortan; Gary May; Cathy Streutker; Norman E. Marcon
/data/revues/00165107/v65i5/S0016510707006153/ | 2011
Sarah Cho; Paul Kortan; Gary May; Norman E. Marcon
/data/revues/00165107/v63i5/S0016510706014672/ | 2011
Douglas A Howell; Michael K. Sanders; Kirk P. Bernadino; Christopher Lawrence; Paul Kortan; Gary May; Raj J. Shah; Yang Chen; Willis G. Parsons; Robert H Hawes; Peter B. Cotton; Adam Slivka; Jawad Ahmad; Glen A. Lehman; Stuart Sherman; David J. Desilets; Horst Neuhaus; Brigitta Schumacher
/data/revues/00165107/v63i5/S001651070600856X/ | 2011
Sarah Cho; Matthew Remedios; Maria Cirocco; Paul Kortan; Gary May; Norman E. Marcon
/data/revues/00165107/v63i5/S0016510706006535/ | 2011
Sarah Cho; Elaine Yong; Simon A. Zanati; Maria Cirocco; Nancy Basset; Paul Kortan; Gary May; Norman E. Marcon
/data/revues/00165107/v61i5/S0016510705009934/ | 2011
Matthew Remedios; Gregory Monkewich; Nancy Basset; Paul Kortan; Gary May; Hironori Yamamoto; Norman E. Marcon
/data/revues/00165107/v61i5/S0016510705007601/ | 2011
Tan Attila; Paul Kortan; Norman E. Marcon